Expertise in
7
conditions

Dr. Karen B. Russell

Oncology
Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, 
Tallahassee, FL 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, 
Tallahassee, FL 

Overview

Karen Russell is an Oncologist practicing medicine in Tallahassee, Florida.

Dr. Russell is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Inflammatory Breast Cancer.

She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 17 clinical trials. Dr. Russell is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Tallahassee Memorial Healthcare

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, Tallahassee, FL 32308

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drugs: Liposomal irinotecan, FOLFOX regimen
Study Phase: Phase 2
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

6 Total Publications

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
Journal: JCO oncology advances
Published: September 01, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Referral may be required

Nemours Children's Health, Tallahassee

2418 E. Plaza Drive, 
Tallahassee, FL 
 (1.5 miles away)
904-697-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

"I’m a pediatric oncologist (cancer specialist) based at the Nemours Children’s Specialty Care, Jacksonville. I’m a triathlete, married with three children, with an interest in finding ways to constantly improve cancer care for children. We returned to Florida, my home state, after travelling the country to complete my medical training. While I was growing up, my mother worked in an OB/GYN office, so I always said I wanted to do the same """"because I love to work with kids."""" At that time, nobody explained to me that OB/GYNs treat women and it’s really pediatricians who treat kids. By medical school, it was clear pediatrics was what I was interested in. I love the personal interactions with families during some of their happiest and also most difficult times. I find the clinical aspects and science behind oncology fascinating. I specialize in cancer care for children and try to find ways to improve the care they receive. I am currently leading the expansion of our treatment protocols for relapsed disease so patients can have more aggressive options if their cancer returns.". Dr. Bradfield is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Bradfield is board certified in American Board Of Pediatrics. Dr. Bradfield is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Tallahassee Memorial Healthcare Inc.

1775 One Healing Pl, 
Tallahassee, FL 
 (2.1 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carolyn Johnston is an Oncologist practicing medicine in Tallahassee, Florida. Dr. Johnston is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Vulvar Cancer, and Sertoli-Leydig Cell Tumor. Dr. Johnston is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Tmh Physician Partners-Cancer & Hematology

1775 One Healing Pl # 2, 
Tallahassee, FL 
 (0.1 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tim Broeseker is an Oncologist practicing medicine in Tallahassee, Florida. Dr. Broeseker is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Broeseker is currently accepting new patients.

Frequently Asked Questions about Dr. Karen B. Russell

How do I make an appointment with Dr. Karen B. Russell?

You can book an appointment with Dr. Karen B. Russell by calling their office at 850-431-5360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Karen B. Russell a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Karen B. Russell is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Karen B. Russell specialize in?

While Dr. Karen B. Russell is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Karen B. Russell participate in research or clinical trials?

Yes. Dr. Karen B. Russell has published 6 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Karen B. Russell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Karen B. Russell accept my insurance?

Dr. Karen B. Russell accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 850-431-5360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Russell's expertise for a condition
ConditionClose
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile